Treatment Center Outreach Toolkit

Integrating Video into Your Website

Part of being a PROVENGE-Certified Treatment Center involves educating patients about PROVENGE. Below are valuable, patient-friendly video resources that can be placed on your practice website to aid the conversation between your healthcare practitioners and patients.

•  Select the video and click the "+" button next to the title.
•  Choose the video size (3 options are provided)
•  Copy the text (HTML code snippet) for the size selected
•  Paste this text into the page on your practice website.

Available Videos

The benefits of PROVENGE and how it works

Learn about PROVENGE, what makes it unique as a personalized immunotherapy for patients with mCRPC, who can benefit from it, potential side effects, and what to expect from treatment, among other key topics.

  • Starting PROVENGE: What to Expect

Speaking to your patients about PROVENGE

PROVENGE has many unique features. Use these tools to explain everything your patient with advanced prostate cancer needs to know about treatment with PROVENGE.

  • Considering PROVENGE: An Experts Perspective

Patient stories

Hear inspiring stories from a range of patients with advanced prostate cancer who have been successfully treated with PROVENGE, in their own voice.

  • Isadore’s Story: Part 1
  • Isadore’s Story: Part 2
  • Rollin's Story
  • Todd's Story: Part 1
  • Todd's Story: Part 2


INDICATION: PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION:
Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia. Closely monitor patients with cardiac or pulmonary conditions.

Thromboembolic events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is intended solely for autologous use and is not tested for transmissible infectious diseases.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please click here for full Prescribing Information.

P-A-01.15-044.00